8-K
filed June 18, 2026, 4:30 PM ET
ticker LAB
CIK 0001162194
other
confidence high
sentiment neutral
materiality 0.20
Stockholders approve 2026 Equity Incentive Plan and ESPP amendment increasing share reserve by 1.2M
STANDARD BIOTOOLS INC.
- Three Class I directors elected: Michael Egholm (236.3M for), Thomas Carey (227.8M for), Eli Casdin (234.7M for).
- Advisory vote on executive compensation approved: 209.8M for, 36.3M against.
- Ratification of PwC as independent auditor approved: 330.2M for, 0.7M against.
- 2026 Equity Incentive Plan approved: 228.3M for, 17.8M against.
- ESPP amendment to increase share reserve by 1.2M shares approved: 237.5M for, 12.3M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
STANDARD BIOTOOLS INC. shareholders approved Advisory Vote on Approval of Executive Compensation at the 2026-04-24 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-04-24
Exact text from the filing
Advisory Vote on Approval of Executive Compensation. The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2025 was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 209,778,412 36,318,595 3,684,591 86,119,046
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
STANDARD BIOTOOLS INC. shareholders approved Approval of the 2026 Equity Incentive Plan at the 2026-04-24 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-04-24
Exact text from the filing
Approval of the 2026 Equity Incentive Plan. The proposal to approve the 2026 Plan was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 228,342,854 17,821,911 3,616,833 86,119,046
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
STANDARD BIOTOOLS INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-04-24 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-04-24
Exact text from the filing
Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was approved by the following vote: Votes For Votes Against Abstentions 330,172,606 652,236 5,075,802
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
STANDARD BIOTOOLS INC. shareholders approved Election of Class I Directors at the 2026-04-24 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-04-24
Exact text from the filing
Election of Class I Directors. The following nominees were elected to serve as Class I directors, to hold office until the Company’s 2029 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Michael Egholm, Ph.D. 236,313,971 13,467,627 86,119,046 Thomas Carey 227,843,498 21,938,100 86,119,046 Eli Casdin 234,717,465 15,064,133 86,119,046
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
STANDARD BIOTOOLS INC. shareholders approved Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan at the 2026-04-24 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-04-24
Exact text from the filing
Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan. The proposal to approve the amendment to the ESPP to increase the shares of common stock reserved thereunder by 1,200,000 shares was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 237,474,844 12,276,507 30,247 86,119,046
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.